Bioventus Class A Inc (BVS) financials

NASDAQ · Health Care

$13.32 -10.39% Close Oct 30, 2026 Live

Bioventus Class A revenue and earnings by year

Bioventus Class A's revenue was $568 million in the fiscal year to December 31, 2025, down 0.9% from the year before. Net income was $22.7 million, 4.0% of revenue. Since the fiscal year to December 31, 2018, revenue has grown 8.6% a year on average.

RevenueNet income
$0$250M$500M
20182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 8 fiscal years

In millions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue568573512512431321340319
Revenue growth-0.9%11.9%0.0%18.8%34.2%-5.6%6.6%—
Gross profit388388328331303234249235
Gross margin68.3%67.7%64.1%64.6%70.3%72.7%73.3%73.6%
Operating income26-51-120-1881016105
Operating margin4.5%-8.9%-23.5%-36.7%2.4%5.0%2.8%1.7%
Net income23-36-156-15919167-12
Net margin4.0%-6.3%-30.5%-31.0%4.5%5.1%2.0%-3.8%
Diluted EPS$0.33-$0.56-$2.49-$2.59————
Free cash flow72388-159553843

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open BVS in Markets.

How Bioventus Class A makes money

Revenue by segment in the quarter to June 27, 2026, as the company reports it.

SegmentRevenueShare
US$134M87.8%
International$18.7M12.2%

See also: BVS valuation and P/E history · BVS returns

No forecast, no recommendation. This page describes Bioventus Class A Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.